Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Alteration of transit time in the SHIME

ABSTRACT: Alteration of transit time in the SHIME

PROVIDER: PRJEB67955 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR12176100.fastq.gz	Fastqsanger.gz
	ERR12176200.fastq.gz	Fastqsanger.gz
	ERR12176300.fastq.gz	Fastqsanger.gz
	ERR12176101.fastq.gz	Fastqsanger.gz
	ERR12176201.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 256

Similar Datasets

TRANSIT

Project description:TRANSIT

| PRJEB39096 | ENA

Gut microbiota response to in vitro transit time variation is mediated by microbial growth rates, nutrient use efficiency and adaptation to in vivo transit time

Project description:Adaptation of transit time in the Simulator of the Human Intestinal Microbial Ecosystem

| PRJEB53900 | ENA

Gut microbial signatures in paediatric Crohn’s disease vary according to disease activity measures and are influenced by proxies of gastrointestinal transit time: an ImageKids study

Project description:Crohn's disease gut microbiome by gastrointestinal transit time

| PRJEB76405 | ENA

In-transit extremity melanoma III

Project description:An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with melphalan in the setting of isolated limb infusion or isolated limb perfusion. Gene expression profiles were obtained from 21 lesions across 19 patients and evaluated for expression that correlated with response to melphalan isolated limb infusion. Chemotherapy response analysis: complete response - CR; partial response - PR; stable disease - SD; progressive disease - PD; not evaluable - n.e.

2011-12-22 | E-GEOD-34599 | biostudies-arrayexpress

In-transit extremity melanoma II

2010-02-26 | GSE19293 | GEO

One-Pot Time-Induced Proteome Integral Solubility Alteration (OPTI-PISA) assay for automated and sensitive drug target identification

Project description:Proteome Integral Solubility Alteration (PISA) assay is widely used for identifying drug targets, but it is labour-, sample and time-consuming. Aiming at enabling automation and greatly reducing the sample amount, we developed One-Pot Time-Induced (OPTI)-PISA. Here we demonstrate OPTI-PISA performance on identifying targets of multiple drugs in cell lysate and scaling down the sample amount to sub-microgram levels, making PISA method suitable to NanoProteomics.

2025-05-06 | PXD050241 | Pride

System-wide profiling of drug residence time by proteome integral solubility alteration assay

Project description:Most drugs used in the clinic and drug candidates target multiple proteins, and thus detailed characterization of their efficacy targets is required. While current methods rely on quantitative measurements at thermodynamic equilibrium, kinetic parameters such as the residence time of a drug on its target provide a better proxy for efficacy in vivo. Here, we present a new Residence Time Proteome Integral Solubility Alteration (ResT-PISA) assay which provides monitoring temporal protein solubility profiles after drug removal in either cell lysate or intact cells, quantifying the lifetime of the drug-target interaction. A compressed version of the assay measures the integral under the off-curve and enables the multiplexing of binding affinity proxy measurements with residence time assessment into a single proteomic analysis. We introduce a combined scoring system for three parametric dimensions to improve prioritization of targets. By providing complementary information to other characteristics of drug-target interaction, ResT-PISA approach can become a useful tool in drug development and precision medicine.

2023-01-06 | PXD034351 | Pride

In-transit extremity melanoma III

2011-12-22 | GSE34599 | GEO

Clinical efficacy of Daikenchuto (DKT: TJ-100) for gastrointestinal symptoms in patients with history of colorectal cancer surgery; crossover study - Gastrointestinal transit time as an indicator -

Project description:Interventions: A group: Oral administration of Daikenchuto (15g/day t.i.d. before meals) for 28 days. Thereafter non-treatment for 28 days. B group: Non-treatment for 28 days. Thereafter oral administration of Daikenchuto (15g/day t.i.d. before meals) for 28 days. Primary outcome(s): 1)total number of elimination of the radiopaque markers 2) oro-cecal transit time 3) GSRS (Japanese Version) Score 4) VAS 5) GVS Study Design: Cross-over Randomized

| 2622806 | ecrin-mdr-crc

In-transit extremity melanoma I

Project description:An evaluation of multifocal lesions from patients with in-transit extremity melanoma to determine if all lesions from a patient harbor homogeneous patterns of gene expression Gene expression profiling studies can help guide treatment for cancer patients by providing tools in the form of gene-expression signatures to characterize a tumor in terms of underlying biology, predicted response to therapy, metastatic progression and/or recurrence. The utility of gene signatures for defining therapeutic strategies in the treatment of extremity in-transit melanoma will be dependent on the genetic relationship between the multifocal lesions typically present in this disease and the extent to which a single lesion is representative of residual tumor burden. Using microarray-based gene expression profiling we examined 43 in-transit melanoma lesions across 17 patients with multifocal disease to determine whether one lesion could accurately characterize the underlying biology and genetic profile of a patient's tumor. Principal component analysis, unsupervised hierarchical clustering, one-way analysis of variance (ANOVA) and gene signatures predictive of chemosensitivity and oncogenic pathway activation showed gene expression patterns to be highly similar (p-values: <0.006; average r = 0.979) between lesions from a single patient but to be significantly different across patients (p<0.05). These findings demonstrate that individual melanoma tumor nodules in patients with multifocal disease are genetically similar and a single lesion can be used to predict response to chemotherapy, evaluate the activation status of oncogenic signaling pathways and characterize other aspects of the biology of an individual patient's disease. These results will facilitate the utilization of gene expression profiling in clinical trials of targeted therapy in melanoma allowing for more rational identification of candidates for specific therapies. Keywords: Disease state analysis

2008-10-30 | GSE10282 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data